C=o Bonded Directly To The Six-membered Hetero Ring Patents (Class 514/350)
  • Patent number: 7125880
    Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: October 24, 2006
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Patent number: 7115563
    Abstract: A composition having a variety of therapeutic and cosmetic uses comprises: (i) a vitamin; (ii) a metal salt that provides metal ions in vivo; and (iii) insulin or a growth hormone. Such a composition is useful for treating, for example, genetic disorders, skin diseases, cancer and viral infections.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: October 3, 2006
    Assignees: Insignion Holding Limited, Veritron Limited
    Inventors: Rafeda M. A. Younis, Karam M. H. Al Sari, Saad M. H. Al Sari, Ahmad M. H. Al Sari
  • Patent number: 7101875
    Abstract: This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 5, 2006
    Assignee: Wyeth
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Patent number: 7074813
    Abstract: The present invention is directed to substituted N?-(arylcarbonyl)-benzhydrazides, N?-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: wherein Ar1, Ar2, and R1–R2 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: July 11, 2006
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, John Drewe, P. Sanjeeva Reddy, Han-Zhong Zhang
  • Patent number: 7060260
    Abstract: Skin care, hair care and hair coloring compositions comprising a water-soluble silk protein as an active ingredient are described. The water-soluble silk protein deposits onto the skin or the natural hair keratin to provide a smooth and durable film to provide added strength for protection against environmental, chemical, and grooming associated damage. The compositions may be in the form of skin care, skin cleansing, or anti-wrinkle products, shampoos, conditioners, lotions, aerosols, gels, mousses, dyes, or bleaches.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: June 13, 2006
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Stephen R. Fahnestock, Thomas M. Schultz
  • Patent number: 7060717
    Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: June 13, 2006
    Assignee: Pfizer Inc
    Inventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
  • Patent number: 7056932
    Abstract: The invention is concerned with novel heterocyclyl substituted 1-alkoxy acetic acid derivatives of formula (I) wherein R1 to R6 and A are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: June 6, 2006
    Assignee: Hoffman-La Roche Inc.
    Inventors: Luca Claudio Gobbi, Katrin Groebke Zbinden, Peter Mohr, Ulrike Obst
  • Patent number: 7056934
    Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: June 6, 2006
    Assignee: Pfizer Inc
    Inventors: Mark Edward Bunnage, John Paul Mathias
  • Patent number: 7045537
    Abstract: This invention relates to protein fiber formation and in particular to methods of producing protein fibers to form a protein structure comprising a plurality of first polypeptide units arranged in a first polypeptide strand and a plurality of second polypeptide units arranged in a second polypeptide strand, the strands preferably forming a coiled coil structure, and in which a first polypeptide unit in the first strand extends beyond a corresponding second polypeptide unit in the second strand in the direction of the strands.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: May 16, 2006
    Assignee: The University of Sussex
    Inventors: Derek N. Woolfson, John Walshaw, Maya J. Pandya, John Colyer
  • Patent number: 7015237
    Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is an integer of from 0 to 6.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: March 21, 2006
    Assignee: Warner-Lambert Company
    Inventors: Nicole Chantel Barvian, David Thomas Connor, Patrick Michael O'Brien, Daniel Fred Ortwine, William Chester Patt, Michael William Wilson
  • Patent number: 7015216
    Abstract: Disclosed are a series of heteroaryl-?-alanine derivatives, compositions containing them, processes for their preparation and their use in medicine.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: March 21, 2006
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Patent number: 7008950
    Abstract: A compound of the formula: wherein R1 and R2 each is H or a hydrocarbon group which may be substituted, or R1 and R2 form a 3- to 8-membered carbo or heterocyclic ring which may be substituted; R3 is H, a lower alkyl which may be substituted or an aromatic group which may be substituted; R4 is (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl; X and Y each is oxygen or sulfur which may be oxidized; and ring A is a benzene ring which may be further substituted, or a salt thereof, is useful for an agent for suppressing neurodegeneration.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: March 7, 2006
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shigenori Ohkawa, Masaki Setoh, Mitsuru Kakihana, Masahiro Okura
  • Patent number: 6992094
    Abstract: The invention concerns novel diarylselenide compounds corresponding to the general formula (I) and the use thereof in pharmaceutical compositions in human or veterinary medicine (in the treatment of dermatological, rheumatic, cardiovascular and ophthalmologic pathologies in particular), or in cosmetic compositions.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: January 31, 2006
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Jean-Michael Bernardon, Philippe Diaz
  • Patent number: 6992095
    Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: January 31, 2006
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Jean-Michel Bernardon, Bruno Charpentier
  • Patent number: 6989396
    Abstract: Compounds and methods of modulating the activity of P-glycoproteins are disclosed. The method utilizes compounds derived from Erythroxylum pervillei. The compounds overcome multidrug resistance and can be used therapeutically to enhance performance of therapeutic drugs, like chemotherapeutic drugs and antibiotics.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: January 24, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: A. Douglas Kinghorn, John M. Pezzuto, Baoliang Cui, Gloria L. Silva, Min You
  • Patent number: 6967211
    Abstract: The present invention relates to an excellent remedial agent for chronic rheumatoid arthritis, comprising an aminostilbazole derivative represented by the following formula [1] or a salt thereof as an active ingredient: A-B-D-E??[1] Wherein A represents heteroaryl or an oxide thereof, B represents ethenylene, D represents phenylene, E represents the formula: —N(R)SO2—G [wherein G represents phenyl, R represents hydrogen, alkyl, or —COR0 (R0 represents alkyl, alkoxy, aryloxy, 5- to 6-membered heteroaryl, heteroarylmethyl, aminoalkylene or cyclicaminoalkylene) or the like].
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: November 22, 2005
    Assignee: Nippon Shinyaku Co. Ltd.
    Inventor: Naoki Inoue
  • Patent number: 6949556
    Abstract: The present invention relates to compounds of general formula (I), wherein R1-R4 have the meanings given in the specification, A is CH2, CHOH or CH—(C1-C3-alkyl), B and C are independently CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group optionally substituted by the substituents listed in the specification.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: September 27, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hartmut Strobel, Paulus Wohlfart
  • Patent number: 6949573
    Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: September 27, 2005
    Assignee: Pfizer Inc
    Inventors: Simon Bailey, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen
  • Patent number: 6919087
    Abstract: An amlodipine maleate pharmaceutical composition is provided with good stability when formulated with a pH within the range of 5.5 to 7, when measured as a 20 wt % aqueous slurry. The stability can also be aided by making the pharmaceutical composition from amlodipine maleate particles having an average particle size of greater than 20 microns, preferably greater than 100 microns.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: July 19, 2005
    Assignee: Synthon BV
    Inventors: Jacobus M. Lemmens, Frans van Dalen, Arlette Vanderheijden
  • Patent number: 6916627
    Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: July 12, 2005
    Assignee: St. Jude Children's Research Hospital
    Inventors: Michael B. Kastan, Christopher Bakkenist
  • Patent number: 6914160
    Abstract: This invention relates to compounds of formula (I)
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: July 5, 2005
    Assignee: Pfizer Inc
    Inventors: Duncan Robert Armour, Andrew Simon Bell, Paul John Edwards, David Ellis, David Hepworth, Mark Llewellyn Lewis, Christopher Ronald Smith
  • Patent number: 6911451
    Abstract: Phenylalanine derivatives of formula (1) are described: wherein L1 is a linker atom or group; X1 is a group selected from —N(R3)CO—, —N(R3)SO2—, —N(R3)C(O)O— or —N(R3)CON(R3a)—; and R is a carboxylic acid or a derivative thereof. The compounds are able to inhibit the binding of a 4 integrins to their ligands and are of use in the prophylaxis and treatment of diseases or disorders involving inflammation.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: June 28, 2005
    Assignee: Celltech R&D Limited
    Inventors: John Robert Porter, John Clifford Head, Graham John Warrellow, Sarah Catherine Archibald
  • Patent number: 6890943
    Abstract: Pyridoxal analogues can be useful for treating B6 deficiency and related diseases; cardiovascular and related diseases; melanoma and related diseases; and symptoms thereof. One such analogue is a compound of the formula: or a pharmaceutically acceptable acid addition salt thereof, in which R1 is alkyl, alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy; alkoxy; dialkylamino; alkanoyloxy; alkanoyloxyaryl; alkoxyalkanoyl; alkoxycarbonyl; dialkylcarbamoyloxy; or aryl, aryloxy, arylthio, or aralkyl, in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy, halo, nitro, or alkanoyloxy. These analogues can be administered, either alone or concurrently with known medications, to treat the above-described diseases.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: May 10, 2005
    Assignees: Medicure Inc., The University of Manitoba
    Inventor: Wasimul Haque
  • Patent number: 6881756
    Abstract: The present invention relates to a method for reducing inflammation in the skin and/or treating inflammatory skin disorders, pain, or pruritis by topically applying a composition comprising totarol or a pharmaceutically-acceptable ester thereof.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: April 19, 2005
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventor: Gerard J. Gendimenico
  • Patent number: 6881742
    Abstract: Novel benzamidoxime derivatives, processes and intermediates for their preparation and their use as fungicides are described. In the context of the present invention, benzamidoxime derivatives are compounds of the formula I where: A is an aryl or hetaryl radical; Y is a straight-chain or branched C1-C4-alkylene group, where one carbon can be replaced by oxygen, nitrogen or sulfur or by a cyclopropyl group; Rn1 are one to five identical or different radicals from the group consisting of: hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C4-haloalkyl, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkoxyalkoxy; R2 is unsubstituted or substituted phenyl-C1-C6-alkyl, thienyl-C1-C4-alkyl, or pyrazolyl-C1-C4-alkyl, Rp3 are one to five identical or different radicals from the group consisting of: hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C4-haloalkyl, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkoxyalkoxy, C1-C6-alkylcarbonyl; n is 0-5; p is, depending on the number of free valencies, 0-4.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: April 19, 2005
    Assignee: BASF Aktiengesellschaft
    Inventors: Joachim Rheinheimer, Karl Eicken, Ingo Rose, Thomas Grote, Eberhard Ammermann, John-Bryan Speakman, Siegfried Strathmann, Gisela Lorenz
  • Patent number: 6878704
    Abstract: Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: April 12, 2005
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Aitken, Gerald Brooks, Steven Dabbs, Colin Henry Frydrych, Steven Howard, Eric Hunt
  • Patent number: 6875440
    Abstract: Termites can be controlled by applying an effective amount of N-[2-chloro-3,5-bis(trifluoromethyl)phenyl]-N?-(2,6-difluorobenzoyl)urea supported on cellulose.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: April 5, 2005
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Seietsu Aki, Hiromi Eguchi
  • Patent number: 6872716
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: March 29, 2005
    Assignee: Sepracor, Inc.
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Patent number: 6846837
    Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: January 25, 2005
    Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
  • Patent number: 6844466
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 18, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Paula Nanette Belloni, Denis John Kertesz, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20040266835
    Abstract: An electron transport system complex II inhibitor comprising 2-pyridinol derivative represented by the general formula [I] 1
    Type: Application
    Filed: August 17, 2004
    Publication date: December 30, 2004
    Inventors: Satoshi Omura, Kazuro Shiomi, Hiroshi Tomoda, Rokuro Masuma, Kiyoshi Kita
  • Publication number: 20040258674
    Abstract: A nutritional supplement for improving cardiovascular health via aiding in preventing, slowing the progression of and/or treating hypertension, the supplement comprising quercetin; and a method for aiding in preventing, slowing the progression of and/or treating hypertension are described.
    Type: Application
    Filed: April 12, 2004
    Publication date: December 23, 2004
    Inventor: Thunder Jalili
  • Patent number: 6833378
    Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: December 21, 2004
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • Publication number: 20040253320
    Abstract: An easily absorbed and well tolerated proportional nutritional supplementation composition and method to be used in patients suffering from deficiency states due to bowel disease that may include malabsorption and inflammatory bowel disease. It is this unique proportional formulation of antacid, calcium, vitamins, minerals and simethicone in lactose free, sorbitol free, gluten free and hypo allergen solution that is the novel invention. This novel invention allows for nutrients to be readily absorbed with little or no side effects that may be experienced when taking conventional supplements. The supplementation contains amounts of vitamins and minerals that are commonly deficient in these states including magnesium, chromium, increased iron, increased folic acid, calcium and fat soluble vitamins.
    Type: Application
    Filed: June 12, 2004
    Publication date: December 16, 2004
    Applicant: Medical Futures Inc.
    Inventor: Pardeep Nijhawan
  • Publication number: 20040254202
    Abstract: The present invention is directed to a method of promoting sleep by topically applying onto the skin a composition that comprises a non-hypnotic, vasoactive agent. The non-hypnotic, vasoactive agent is highly effective in providing for the improved quality of sleep through the use of topical application.
    Type: Application
    Filed: June 13, 2003
    Publication date: December 16, 2004
    Applicant: The Procter & Gamble Company
    Inventor: James Patrick Ebel
  • Publication number: 20040253322
    Abstract: This invention refers to the preparation for elimination of neuropathies in diabetes. The preparation contains a combination of minerals and plant extracts. By its ionic exchange, the invention reduces considerably the process of apoptosis of nerve-cells, eliminates the process of activation of the immunologic system, and stops the immunologic reaction of auto-destruction of nerve-cells. Depositing of immunoglobulin on axons is absent, and neuropathic pain disappears. Furthermore, the preparation reduces the activity of free radicals, improves the regulation of glycemia and improves the recovery of axons which are already damaged.
    Type: Application
    Filed: December 13, 2002
    Publication date: December 16, 2004
    Inventors: Robert Basic, Milivoj Slijepcevic, Mirko Hadzija, Marijana Hadzija
  • Publication number: 20040248819
    Abstract: The present invention relates generally to a composition for use in the prophylaxis and/or treatment of one or more symptoms caused or exacerbated by consumption fo alcolhol which composition comprises: (1) fructose and (2) fructose-containing oligosacchraride.
    Type: Application
    Filed: June 28, 2004
    Publication date: December 9, 2004
    Inventor: Neil Roland McGregor
  • Patent number: 6828337
    Abstract: This invention relates to new RAR selective retinoid agonists of formula I wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 7, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20040235907
    Abstract: Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. Also disclosed are methods directed to concurrently administering a therapeutically effective amount of a compound with other compounds known in the treatment of diabetes mellitus. In one embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of insulin. In another embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of a hypoglycemic compound.
    Type: Application
    Filed: June 30, 2004
    Publication date: November 25, 2004
    Applicant: Medicure, Inc.
    Inventors: Rajat Sethi, Wasimul Haque
  • Publication number: 20040235718
    Abstract: The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.
    Type: Application
    Filed: June 21, 2004
    Publication date: November 25, 2004
    Inventors: Michael Becker-Andre, Hans Dieplinger, Charlotte Teunissen, Lidija Jerkovic
  • Patent number: 6815415
    Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 9, 2004
    Assignee: Rhode Island Hospital
    Inventors: Jack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
  • Publication number: 20040213857
    Abstract: The invention relates to pharmaceutical or dietary unit dosage form, which can be swallowed easily, consisting essentially of vitamins, minerals and trace elements recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, DHA and a pharmaceutically or dietetically suitable carrier.
    Type: Application
    Filed: April 15, 2004
    Publication date: October 28, 2004
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Fabio Soldati, Lara Ambrosetti-Giudici
  • Publication number: 20040204382
    Abstract: The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates.
    Type: Application
    Filed: April 8, 2003
    Publication date: October 14, 2004
    Inventors: Janeel Henderson, H. DeWayne Ashmead
  • Publication number: 20040192649
    Abstract: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of a terpene alcohol and a safe and effective amount of a retinoid; a safe and effective amount of a terpene alcohol and a safe and effective amount of a peptide; a safe and effective amount of a retinoid and a safe and effective amount of a peptide; a safe and effective amount of tocopherol sorbate; or a safe and effective amount of a vitamin B3 compound.
    Type: Application
    Filed: March 31, 2004
    Publication date: September 30, 2004
    Inventors: Donald Lynn Bissett, Laura Jackson Goodman, Elizabeth Ann Jewell-Motz
  • Patent number: 6797708
    Abstract: This invention provides substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 28, 2004
    Assignee: Wyeth
    Inventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Publication number: 20040186078
    Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: 1
    Type: Application
    Filed: April 5, 2004
    Publication date: September 23, 2004
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, John Drewe, P. Sanjeeva Reddy, Han-Zhong Zhang
  • Publication number: 20040186144
    Abstract: The invention provides a method for treating visual field defects in a mammal in need thereof by administering an effective amount of vitamin B6 to the mammal. Novel compositions containing a GABAergic drug and vitamin B6 are also provided.
    Type: Application
    Filed: February 10, 2004
    Publication date: September 23, 2004
    Inventor: Charles R. Ashby
  • Patent number: 6794396
    Abstract: A class of substituted pyridines that are useful for inhibiting the activity of cholesteryl ester transfer protein, and have the structural formula (IA), wherein R2, R3, R4, R5, and R6 are defined in the claims.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: September 21, 2004
    Assignee: Pharmacia Corporation
    Inventors: Len F. Lee, Kevin C. Glenn, Daniel T. Connolly, David G. Corley, Daniel L. Flynn, Ashton T. Hamme, Shridhar G. Hegde, Michele A. Melton, Roger J. Schilling, James A. Sikorski, Nancy N. Wall, Jeffery A. Zablocki
  • Patent number: 6794377
    Abstract: Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations including their use as antiarrhythmic active compounds, for example, for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutters.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: September 21, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Peukert, Joachim Brendel, Horst Hemmerle, Heinz-Werner Kleemann
  • Patent number: 6794397
    Abstract: The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula V: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and R11 is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted. The present invention also relates to the discovery that compounds having Formula V are activators of caspases and inducers of apoptosis. Therefore, the compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: September 21, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe